An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes (HES) - 01/02/21
Doi : 10.1016/j.jaci.2020.12.505
Michael Chen 1, Praveen Akuthota, MD 2, Timothy Lax 3, Sameer Mathur, MD PhD FAAAAI 4, Princess Ogbogu, MD FAAAAI 5, Thanai Pongdee, MD FAAAAI 6, Marc Rothenberg, MD PhD FAAAAI 7, Florence Roufosse 8, Dagmar Simon 9, Miguel Stein 10, Sa Wang 11, Michael Wechsler, MD 12, Amy Klion, MD 13, Bruce Bochner, MD FAAAAI 1
1 Northwestern University Feinberg School of Medicine, Chicago, IL
2 University of California San Diego, La Jolla, CA
3 Beth Israel Deaconess Medical Center, Boston, MA
4 University of Wisconsin, Madison, WI
5 The Ohio State University Wexner Medical Center, Columbus, OH
6 Mayo Clinic, Rochester, MN
7 Cincinnati Children's Hospital Medical Center, Cincinnati, OH
8 Hôpital Erasme, Université libre de Bruxelles, Brussels, Belgium
9 Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
10 Edith Wolfson Medical Center, Tel Aviv University, Holon, Israel
11 MD Anderson Cancer Center, Houston, TX
12 National Jewish Health, Denver, CO
13 National Institutes of Health, Bethesda MD
445
Le texte complet de cet article est disponible en PDF.Plan
© 2020
Publié par Elsevier Masson SAS.
Vol 147 - N° 2S
P. AB139 - février 2021 Retour au numéro
Article précédent
- Impact of Baseline Blood Eosinophil Count on Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome
- Marc Rothenberg, Florence Roufosse, Stanislas Faguer, Gerald Gleich, Jean-Emmanuel Kahn, Jonathan Steinfeld, Namhee Kwon, Jane Bentley, Steve Yancey
- Impact of mepolizumab on symptom severity in patients with hypereosinophilic syndrome
- Florence Roufosse, Joseph Butterfield, Robyn von Maltzahn, Linda Nelsen, Jane Bentley, Namhee Kwon, Jonathan Steinfeld
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?